In this special episode of Healthcare Unfiltered, Dr. Tanios Bekaii-Saab, of the Mayo Clinic, joins Dr. Chadi Nabhan to discuss the most groundbreaking studies unveiled at the 2024 ASCO GI Symposium, including an examination of the crucial, previously reported data from IMbrave050 and EMERALD-1.
Liver Cancer
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
Drs. Finn and Yopp discuss the challenges of defining high-risk patient populations in adjuvant therapy trials for HCC.
Nivolumab plus ipilimumab provided a higher OS and ORR rate, supporting the combination as a potential standard of care.
Dr. Pasche discusses the trial that led to the TheraBionic P1 device's regulatory approval by the FDA.
Dr. Weinberg provided his perspective on the CheckMate 9DW expanded analyses, as well as multiple studies in CRC.
Previous data pointed to the benefit of adjuvant immunotherapy for patients with HCC through the use of CIK cells.
Dr. Lieu details practice-changing studies from ASCO GI 2025, including CheckMate-9DW, CheckMate 8HW, and BREAKWATER.
In EMERALD-1, investigators analyzed the combination of durvalumab plus bevacizumab and TACE versus placebo with TACE.
Additional analyses from the CheckMate 9DW study shed further light on the clinical efficacy and safety of ipi/nivo for uHCC.
The study reinforces the potential of triplet blockade with casdozo, atezo, and bev as a viable approach for managing uHCC.
Featured Podcast
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.